UA85576C2 - Тетразольные соединения и их применение в качестве метаботропических антагонистов рецепторов глутамата - Google Patents

Тетразольные соединения и их применение в качестве метаботропических антагонистов рецепторов глутамата

Info

Publication number
UA85576C2
UA85576C2 UAA200608678A UAA200608678A UA85576C2 UA 85576 C2 UA85576 C2 UA 85576C2 UA A200608678 A UAA200608678 A UA A200608678A UA A200608678 A UAA200608678 A UA A200608678A UA 85576 C2 UA85576 C2 UA 85576C2
Authority
UA
Ukraine
Prior art keywords
antagonits
glutamate receptor
metabotropic glutamate
tetrazole compounds
compounds
Prior art date
Application number
UAA200608678A
Other languages
English (en)
Ukrainian (uk)
Inventor
Мартин Йохансон
Александер Минидис
Карин Стааф
Дейвид Венсбо
Доналд Маклеод
Луиз Эдвардс
Метвин Айзек
Энн О'Браен
Абдельмалик Слесси
Тао Синь
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886129&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA85576(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of UA85576C2 publication Critical patent/UA85576C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UAA200608678A 2004-02-18 2005-02-17 Тетразольные соединения и их применение в качестве метаботропических антагонистов рецепторов глутамата UA85576C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54529104P 2004-02-18 2004-02-18

Publications (1)

Publication Number Publication Date
UA85576C2 true UA85576C2 (ru) 2009-02-10

Family

ID=34886129

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200608678A UA85576C2 (ru) 2004-02-18 2005-02-17 Тетразольные соединения и их применение в качестве метаботропических антагонистов рецепторов глутамата

Country Status (20)

Country Link
US (2) US20070197549A1 (ru)
EP (1) EP1716125B1 (ru)
JP (1) JP5084269B2 (ru)
KR (1) KR20070027504A (ru)
CN (2) CN1918137B (ru)
AR (1) AR047812A1 (ru)
AU (1) AU2005214379B2 (ru)
BR (1) BRPI0507498A (ru)
CA (1) CA2556263A1 (ru)
IL (1) IL177056A0 (ru)
MX (1) MXPA06009019A (ru)
MY (1) MY145075A (ru)
NO (1) NO20063470L (ru)
RU (1) RU2372347C2 (ru)
SG (1) SG150539A1 (ru)
TW (1) TW200533664A (ru)
UA (1) UA85576C2 (ru)
UY (1) UY28763A1 (ru)
WO (1) WO2005080356A1 (ru)
ZA (1) ZA200606594B (ru)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005214380A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
SG150539A1 (en) * 2004-02-18 2009-03-30 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
JPWO2006080533A1 (ja) * 2005-01-31 2008-06-19 持田製薬株式会社 ３−アミノ−１，２，４−トリアゾール誘導体
US7964619B2 (en) * 2005-06-03 2011-06-21 The University Of North Carolina At Chapel Hill Teraryl components as antiparasitic agents
AU2006202083A1 (en) * 2005-06-03 2006-12-21 Reto Brun Linear dicationic terphenyls and their aza analogues as antiparasitic agents
UY29796A1 (es) 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
HUP0500921A2 (en) * 2005-10-05 2007-07-30 Richter Gedeon Nyrt Tetrazole derivatives, process for their preparation and their use
TWI417095B (zh) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200811179A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators VI
TW200811157A (en) 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
TW200808800A (en) * 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
AR065622A1 (es) * 2007-03-07 2009-06-17 Ortho Mcneil Janssen Pharm Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona
TW200900065A (en) * 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
PL2203439T3 (pl) 2007-09-14 2011-06-30 Addex Pharmaceuticals Sa 1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony
WO2009033702A1 (en) 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
CA2698929C (en) * 2007-09-14 2016-01-19 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones
EP2231647A4 (en) * 2007-10-19 2011-08-31 Astrazeneca Ab TETRAZONE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS (MGLURS)
KR20100089091A (ko) * 2007-10-26 2010-08-11 아스트라제네카 아베 Ｍｇｌｕｒ5의 조절제로서의 아미노 1,2,4-트리아졸 유도체
WO2009054785A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole ether derivatives as modulators of mglur5
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8012976B2 (en) 2008-08-06 2011-09-06 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
MX2011003691A (es) 2008-10-16 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzomorfolina como moduladores de los receptores de glutamato metabotropico.
ES2401691T3 (es) 2008-11-28 2013-04-23 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato
KR20110089868A (ko) * 2008-12-12 2011-08-09 아스트라제네카 아베 ４-［４-메틸-５-(ｃ1-10알킬티오／ｃ5-10아릴-ｃ1-6알킬티오)-４ｈ-１,２,４-트리아졸-3-일］피리딘을 제조하기 위한 신규 방법
JP2012512868A (ja) * 2008-12-18 2012-06-07 アストラゼネカ・アクチエボラーグ ３−｛４−メチル−５−［（１ｒ）−１−（２−（３−メチルフェニル−２ｈ−テトラゾール−５−イル）−エトキシ］−４ｈ−［１，２，４］トリアゾール−３−イル｝−ピリジン、４−メチル−３−メチルチオ−５−（３−ピリジル）−１，２，４−トリアゾール、および（１ｒ）−１−［２−（３−メチルフェニル）−２ｈ−テトラゾール−５−イル］エタノールの製造方法
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US20100273805A1 (en) * 2009-04-23 2010-10-28 Astrazeneca Ab Sulphide bridged derivatives as modulators of mglur5 733
JP5634506B2 (ja) 2009-05-12 2014-12-03 ジャンセン ファーマシューティカルズ， インコーポレイテッド １，２，３−トリアゾロ［４，３−ａ］ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用
AU2010246607B2 (en) 2009-05-12 2012-09-27 Addex Pharma S.A. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102725281A (zh) * 2009-06-05 2012-10-10 奥斯陆大学医院公司 作为wtn通路抑制剂的氮杂茂类衍生物
WO2011082010A1 (en) * 2009-12-29 2011-07-07 Eli Lilly And Company Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
WO2011097334A1 (en) 2010-02-03 2011-08-11 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
HUE030794T2 (en) 2010-02-08 2017-06-28 Medivation Technologies Inc Synthesis Processes of Dihydro-Pyrido-Phthalazinone Derivatives
DK2630146T3 (da) 2010-10-21 2020-08-10 Medivation Tech Llc Krystallinsk (8S,9R)-5-fluor-8-(4-fluorphenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phtalazin-3(7H)-on-tosylatsalt
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP5852665B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
JP5852666B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
CA2820800A1 (en) 2010-12-08 2012-06-14 Oslo University Hospital Hf Triazole derivatives as wnt signaling pathway inhibitors
KR101235100B1 (ko) * 2010-12-15 2013-02-20 서강대학교산학협력단 트리아졸을 포함하는 삼중연결고리 3차 아민 화합물, 이의 제조방법 및 응용
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EP3066084A1 (en) 2013-11-07 2016-09-14 Medivation Technologies, Inc. Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
KR20220038826A (ko) 2014-01-21 2022-03-29 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
KR20200036063A (ko) 2014-01-21 2020-04-06 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
CN111269192A (zh) * 2020-02-25 2020-06-12 成都睿智化学研究有限公司 一种5-羟甲基四氮唑及其衍生物的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509153A (en) * 1967-03-24 1970-04-28 Miles Lab 5-phenyl (or 5-phenylalkyl)-2-(omega-(4-phenyl-1-piperazinyl)alkyl)tetrazoles
US4663332A (en) * 1985-10-10 1987-05-05 Hoffman-La Roche Inc. 5-substituted N-alkylated tetrazoles
EP0596933A1 (en) 1991-08-03 1994-05-18 Smithkline Beecham Plc 5-ht4 receptor antagonists
GB9205320D0 (en) * 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
DE10023430A1 (de) 2000-05-12 2001-11-15 Bayer Ag Substituierte N-Benzoyl-N'-(tetrazolylphenyl)-harnstoffe
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
CA2462289C (en) * 2001-10-04 2010-02-23 Nicholas D. Cosford Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
AU2002359714B2 (en) * 2001-12-18 2006-12-21 Merck Sharp & Dohme Corp. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
WO2003077918A1 (en) * 2002-03-12 2003-09-25 Merck & Co., Inc. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
KR100557093B1 (ko) * 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
SG150539A1 (en) * 2004-02-18 2009-03-30 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonists

Also Published As

Publication number Publication date
NO20063470L (no) 2006-11-17
SG150539A1 (en) 2009-03-30
WO2005080356A1 (en) 2005-09-01
BRPI0507498A (pt) 2007-07-10
MY145075A (en) 2011-12-15
CN1918137B (zh) 2012-08-01
RU2372347C2 (ru) 2009-11-10
US7691892B2 (en) 2010-04-06
EP1716125B1 (en) 2013-06-19
JP2007523182A (ja) 2007-08-16
EP1716125A1 (en) 2006-11-02
CN1918137A (zh) 2007-02-21
TW200533664A (en) 2005-10-16
US20060004021A1 (en) 2006-01-05
US20070197549A1 (en) 2007-08-23
JP5084269B2 (ja) 2012-11-28
KR20070027504A (ko) 2007-03-09
RU2006127573A (ru) 2008-03-27
ZA200606594B (en) 2007-11-28
MXPA06009019A (es) 2007-03-08
UY28763A1 (es) 2005-06-30
AU2005214379A1 (en) 2005-09-01
AU2005214379B2 (en) 2012-03-22
AR047812A1 (es) 2006-02-22
IL177056A0 (en) 2006-12-10
CN101845023A (zh) 2010-09-29
CA2556263A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
UA85576C2 (ru) Тетразольные соединения и их применение в качестве метаботропических антагонистов рецепторов глутамата
TW200604183A (en) Triazole compounds and their use as metabotropic glutamate receptor antagonists
SE0403171D0 (sv) New compounds
MY140235A (en) New benzimidazole derivatives
SE0202133D0 (sv) Novel compounds
TW200613272A (en) Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
TW200745114A (en) Novel compounds
TW200833670A (en) Novel compounds 569
IL189987A0 (en) Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists
TW200613243A (en) Novel compounds
WO2006011050A3 (en) Pyridine derivatives
TW200745084A (en) Novel compounds
TW200732313A (en) Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
TW200512201A (en) New heterocyclic amides
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
PT2280706E (pt) Composições compreendendo derivados de benzeno que activam lipase de lipoproteína
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
TW200738658A (en) Novel compounds
TW200604197A (en) New compounds
TW200716529A (en) New compounds II
TW200626553A (en) Novel compounds
TW200736227A (en) New compounds III
TW200639156A (en) New compounds
TW200745122A (en) New compounds I
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.